Earnings summaries and quarterly performance for ALNYLAM PHARMACEUTICALS.
Executive leadership at ALNYLAM PHARMACEUTICALS.
Yvonne Greenstreet
Detailed
Chief Executive Officer
CEO
JP
Jeffrey Poulton
Detailed
Executive Vice President, Chief Financial Officer
KF
Kevin Fitzgerald
Detailed
Executive Vice President, Chief Scientific Officer
PG
Pushkal Garg
Detailed
Executive Vice President, Chief Research and Development Officer
RH
Robert Hesslein
Detailed
Executive Vice President, Chief Legal Officer and Secretary
TT
Tolga Tanguler
Detailed
Executive Vice President, Chief Commercial Officer
Board of directors at ALNYLAM PHARMACEUTICALS.
AS
Amy Schulman
Detailed
Chair of the Board
CB
Carolyn Bertozzi
Detailed
Director
CR
Colleen Reitan
Detailed
Director
DP
David Pyott
Detailed
Director
DA
Dennis Ausiello
Detailed
Director
ES
Elliott Sigal
Detailed
Director
MH
Margaret Hamburg
Detailed
Director
MB
Michael Bonney
Detailed
Director
OB
Olivier Brandicourt
Detailed
Director
PK
Peter Kellogg
Detailed
Director
Research analysts who have asked questions during ALNYLAM PHARMACEUTICALS earnings calls.
JF
Jessica Fye
JPMorgan Chase & Co.
6 questions for ALNY
Also covers: ALKS, AMRN, ASND +23 more
RB
Ritu Baral
TD Cowen
6 questions for ALNY
Also covers: ACAD, ATAI, BOLD +11 more
TA
Tazeen Ahmad
Bank of America
6 questions for ALNY
Also covers: ACAD, APLS, ARGX +20 more
LI
Luca Issi
RBC Capital Markets
5 questions for ALNY
Also covers: ADVM, ALLO, AMGN +12 more
Gena Wang
Barclays
4 questions for ALNY
Also covers: BCRX, BLUE, BMRN +12 more
Paul Matteis
Stifel
4 questions for ALNY
Also covers: ABOS, ACAD, ALKS +11 more
Salveen Richter
Goldman Sachs
4 questions for ALNY
Also covers: ACAD, AGIO, ALLO +20 more
EM
Eliana Merle
UBS
3 questions for ALNY
Also covers: APLS, ARVN, ARWR +17 more
Gary Nachman
Raymond James
3 questions for ALNY
Also covers: ABBV, ACHV, ADMA +9 more
MR
Maury Raycroft
Jefferies
3 questions for ALNY
Also covers: ABEO, ARWR, BCRX +11 more
AJ
Adithya Jayaraman
Evercore
2 questions for ALNY
HW
Huidong Wang
Barclays
2 questions for ALNY
Also covers: BCRX, BEAM, BLUE +15 more
JP
Julian Pino
Jefferies
2 questions for ALNY
Also covers: ACAD, ALEC, BMRN +2 more
KB
Konstantinos Biliouris
BMO Capital Markets
2 questions for ALNY
Also covers: BEAM, BMRN, LEGN +3 more
Kostas Biliouris
BMO Capital Markets
2 questions for ALNY
Also covers: BMRN, LEGN, NTLA +2 more
MU
Michael Ulz
Morgan Stanley
2 questions for ALNY
Also covers: ARWR, FATE, GUTS +8 more
DL
David Lebowitz
Citigroup Inc.
1 question for ALNY
Also covers: ARWR, ASND, BPMC +11 more
EM
Ellie Merle
UBS Group AG
1 question for ALNY
Also covers: ALT, ARVN, ARWR +12 more
MF
Mani Foroohar
Leerink Partners
1 question for ALNY
Also covers: ADVM, ARWR, BBIO +9 more
MR
Maurice Raycroft
Jefferies Financial Group
1 question for ALNY
Also covers: ABEO, AFMD, ARWR +14 more
TV
Teresa Vitali
Scotiabank
1 question for ALNY
Also covers: GERN
TV
Theresa Vitelle
Scotiabank
1 question for ALNY
Tommie Reerink
Goldman Sachs
1 question for ALNY
Also covers: ATRA, BMRN, BPMC +2 more
Recent press releases and 8-K filings for ALNY.
Alnylam Outlines Ambitious 2030 Growth Strategy and Reports Strong 2025 Financials
ALNY
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Alnylam exceeded its P5x25 goals by the end of 2025, reporting nearly $3 billion in combined net product revenues, an 81% year-over-year growth, largely due to the landmark approval and launch of Amvuttra for ATTR cardiomyopathy.
- The company projects 2026 net product revenue guidance of $4.9 billion to $5.3 billion, with the TTR franchise expected to contribute $4.4 billion to $4.7 billion, representing 83% growth at the midpoint.
- Alnylam unveiled its Alnylam 2030 goals, targeting 25% or greater total revenue CAGR through 2030, approximately 30% Non-GAAP operating margin, and global TTR leadership.
- Key to the 2030 strategy is the launch of Nucresiran, a next-generation TTR silencer, in polyneuropathy by 2028 and cardiomyopathy by 2030, alongside expanding the pipeline to over 40 clinical programs across 10 tissue types.
5 days ago
Alnylam Reports Strong 2025 Results and Outlines Ambitious 2030 Growth Strategy
ALNY
Guidance Update
Revenue Acceleration/Inflection
Product Launch
- Alnylam reported nearly $3 billion in combined net product revenues for 2025, representing an 81% year-over-year growth, and is on track for Non-GAAP profitability.
- The company provided 2026 net product revenue guidance of $4.9 to $5.3 billion, with the TTR franchise expected to contribute $4.4-$4.7 billion, indicating 83% growth at the midpoint.
- Alnylam announced ambitious Alnylam 2030 goals, including aspiring to generate well over $10 billion in annual revenues, a 25% or greater total revenue CAGR, and approximately 30% Non-GAAP operating margin by the end of 2030.
- Key pipeline developments include the planned launch of Nucresiran, a next-generation TTR silencer, in polyneuropathy by 2028 and cardiomyopathy by 2030, offering 95% knockdown and biannual dosing.
5 days ago
Alnylam Reports Strong 2025 Performance and Outlines Ambitious 2030 Growth Strategy
ALNY
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Alnylam announced nearly $3 billion in combined net product revenues for 2025, representing an 81% year-over-year growth, with the TTR franchise contributing $2.5 billion.
- The company provided 2026 net product revenue guidance of $4.9 to $5.3 billion, projecting 83% growth at the midpoint for the TTR franchise to $4.4-$4.7 billion.
- Alnylam unveiled new "Alnylam 2030" goals, targeting over $10 billion in annual revenues by 2030, a 25% or greater total revenue CAGR, and an approximately 30% non-GAAP operating margin through 2030.
- Key strategic initiatives include the planned launch of Nucresiran, a next-generation TTR silencer, in polyneuropathy by 2028 and cardiomyopathy by 2030, alongside expanding the clinical pipeline to over 40 programs across 10 tissue types.
5 days ago
Alnylam Pharmaceuticals Announces "Alnylam 2030" Strategy and Provides 2025 Preliminary Results and 2026 Guidance
ALNY
Earnings
Guidance Update
New Projects/Investments
- Alnylam Pharmaceuticals launched its new five-year "Alnylam 2030" strategy on January 11, 2026, aiming for global TTR leadership, 25%+ total revenue CAGR through 2030, and approximately 30% non-GAAP operating margin.
- The company reported preliminary full year 2025 net product revenues of $2,987 million, reflecting 81% growth over 2024, with total TTR revenues reaching $2,487 million.
- For full year 2026, Alnylam provided combined net product revenue guidance of $4,900 million to $5,300 million, representing 71% growth compared to 2025 at the mid-point.
- 2026 pipeline goals include advancing Phase 3 trials for nucresiran and zilebesiran, completing enrollment for mivelsiran's Phase 2 trial in cerebral amyloid angiopathy, and initiating a Phase 2 trial for ALN-4324 in type 2 diabetes mellitus.
5 days ago
Alnylam Pharmaceuticals Launches New Strategy and Provides Financial Guidance
ALNY
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Alnylam Pharmaceuticals launched its "Alnylam 2030" strategy to scale operations, achieve global TTR leadership, and drive long-term growth, targeting a 25%+ total revenue CAGR through year-end 2030 and a ~30% non-GAAP operating margin.
- The company reported preliminary full year 2025 net product revenues of $2,987 million, an 81% growth compared to 2024, primarily driven by total TTR revenues of $2,487 million (103% growth).
- For 2026, Alnylam provided combined net product revenue guidance of $4,900 million to $5,300 million, representing 71% growth at the mid-point versus 2025.
- Alnylam also detailed 2026 pipeline goals, including advancing Phase 3 trials for nucresiran and zilebesiran, and initiating multiple Phase 2 trials and new Investigational New Drug (IND) applications.
6 days ago
Acuitas Therapeutics Acquires Majority Stake in RNA Technologies & Therapeutics
ALNY
M&A
New Projects/Investments
- Acuitas Therapeutics has acquired a majority stake in RNA Technologies & Therapeutics (RNA T&T), a company specializing in the design, optimization, and manufacture of high-quality RNA constructs.
- This strategic investment aims to expand RNA T&T's operations and integrate its expertise with Acuitas' lipid nanoparticle (LNP) delivery systems, providing partners with streamlined access to combined know-how for RNA-LNP therapeutics.
- The collaboration is expected to reduce development complexity, accelerate clinical timelines, and preemptively mitigate risk across multiple programs.
- Acuitas' LNP technology has previously enabled the Pfizer-BioNTech COVID-19 vaccine and ONPATTRO® by Alnylam Pharmaceuticals.
Jan 8, 2026, 2:00 PM
Alnylam Announces $250 Million Manufacturing Facility Expansion
ALNY
New Projects/Investments
- Alnylam Pharmaceuticals (ALNY) plans a $250 million investment to expand its manufacturing facility in Norton, Massachusetts.
- This expansion will integrate the siRELIS™ enzymatic ligation platform, which is expected to substantially increase manufacturing capacity and significantly reduce production costs.
- The new capabilities are projected to become fully operational by late 2027.
- The U.S. Food and Drug Administration (FDA) has accepted the siRELIS™ platform into its Emerging Technology Program, which will accelerate global regulatory engagement.
Dec 17, 2025, 1:00 PM
Alnylam Announces Partial Repurchase of Convertible Senior Notes
ALNY
- Alnylam Pharmaceuticals, Inc. has entered into agreements to repurchase approximately $34.4 million aggregate principal amount of its 1.00% convertible senior notes due 2027.
- The total repurchase cost, including accrued and unpaid interest, is approximately $51.9 million.
- Following these transactions, approximately $362.8 million aggregate principal amount of the notes will remain outstanding.
Dec 11, 2025, 12:25 PM
Alnylam Provides Update on Amvuttra Launch, Pipeline, and Strategic Goals
ALNY
Product Launch
New Projects/Investments
Guidance Update
- Alnylam is on the cusp of delivering its P5x25 goals, which include achieving sustainable non-GAAP profitability, and plans to announce new objectives early next year.
- The Amvuttra cardiomyopathy launch has had a "terrific start," with patient volume demand doubling in the last quarter and broad utilization across first-line and second-line patients. The company expects continued growth in the TTR market, where only 20% of an estimated 150,000 US patients are currently diagnosed.
- Alnylam is advancing Nucresiran, its next-generation TTR program, with Phase 3 studies targeting market entry around 2028 for polyneuropathy and 2030 for cardiomyopathy, offering >95% TTR knockdown and a twice-a-year regimen.
- The company has initiated a Phase 1 study for its Huntington's disease program, which aims to knock down the full-length Huntington protein and exon one fragment.
Nov 19, 2025, 11:30 AM
Alnylam Discusses Strong Amvuttra Launch and Pipeline at Jefferies Conference
ALNY
Product Launch
Guidance Update
New Projects/Investments
- Alnylam, a leading RNAi company, is on the cusp of achieving its P5x25 goals, which include sustainable non-GAAP profitability, and will announce new objectives early next year.
- The launch of Amvuttra for cardiomyopathy has seen a "terrific start", with access to key healthcare systems achieved rapidly and patient volume demand doubling in the last quarter (Q3 2025), leading to increased guidance.
- The company anticipates continued growth in the TTR cardiomyopathy market, where only 20% of an estimated 300,000 global patients are currently diagnosed, and is advancing Nucresiran, a next-generation TTR therapy, with potential launches in 2028 (polyneuropathy) and 2030 (cardiomyopathy).
- Alnylam's clinical pipeline includes several potential blockbuster opportunities, such as zilebesiran for hypertension and a promising Phase 1 program for Huntington's disease, which is considered a key catalyst.
Nov 19, 2025, 11:30 AM
Quarterly earnings call transcripts for ALNYLAM PHARMACEUTICALS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more